Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.42 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.42 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18123247 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL13931096 | 0.82 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL13931103 | 0.82 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL2549836 | 0.80 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL17447332 | 0.80 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL72238 | 0.78 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL24323607 | 0.77 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL34474751 | 0.77 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL6134116 | 0.75 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL13931093 | 0.75 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3277687-B1 | 7-(MORPHOLIN-4-YL)PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES WHICH ARE USEFUL FOR THE TREATMENT OF IMMUNE OR INFLAMMATORY DISEASES OR CANCER | Celon Pharma Sa (PL) | 2019-10-30 | — | — | EP | disclosed |